The Oncology Institute, Inc. STLN
Set alert
6.22 USD -0.03 -0.51%
As of Nov 3, 11:49 AM ET
6.19 Day range 6.36
2.32 52-week range 7.13
- YTD
- +74.67%
- 1 year
- +38.49%
- Open
- 6.25
- Prev close
- 6.25
- Mkt cap
- 633.41M
- Vol
- 306.49K
- Avg vol
- 1.37M
- EPS
- -0.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.19
- High
- 6.36
YTD chart
Signals (54)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
Newest 20 of 54.
Financials — quick view
STLN Revenue — quarterly 161.28M
STLN Net income — quarterly -8.24M
STLN EPS — quarterly -0.08
News
- Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
- Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
- Oncology Institute (NASDAQ:STLN) Shares Climb 6.1% – Should You Buy?
- Cedar Grove Capital Q3 2026 Portfolio Update
- Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
- Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Starling Oncology to Participate in Wells Fargo Healthcare Conference
- Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
- Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Your note
Sign in to keep a note on STLN — it syncs with the Stock Master app.